Bastien Cabarrou

Advances in diagnosis and treatment of bladder cancer

cGAS-STING, inflammasomes and pyroptosis: an overview of crosstalk mechanism of activation and regulation

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis.